레보티록신

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Uncorrected adrenal insufficiency (Addison's disease)
• Acute myocardial infarction (general precaution)

이상반응

• Tachycardia
• Excitability
• Nervousness
• Excessive panting
• Unmasking of Addison's disease

약물 상호작용

• Catecholamines · Actions of catecholamines are enhanced by thyroxine · moderate
• Sympathomimetics · Actions of sympathomimetics are enhanced by thyroxine · moderate
• Insulin · Altered insulin requirements; monitor carefully during initiation of therapy · moderate
• Oestrogens · May increase thyroid requirements by increasing thyroxine-binding globulin · moderate
• Ciclosporin · Therapeutic effect may be reduced by thyroid hormones · moderate
• Digoxin · Therapeutic effect may be reduced by thyroid hormones · moderate
• Digitoxin · Therapeutic effect may be reduced by thyroid hormones · moderate
• Ketamine · Tachycardia and hypertension may develop when given to patients receiving thyroid hormones · major

모니터링

• Serum total T4 levels (pre-pill trough and 4-8 hours post-pill peak)
• Clinical response (resolution of lethargy, weight gain, dermatological signs)
• Signs of thyrotoxicosis (panting, tachycardia, hyperactivity)
• Blood glucose in diabetic patients

과용량

Clinical signs of overdosage (thyrotoxicosis) include **tachycardia**, **excitability**, **nervousness**, and **excessive panting**. Treatment involves withholding the medication until signs resolve, then restarting at a lower dose. Acute massive overdose may require gastrointestinal decontamination and supportive care (e.g., beta-blockers for severe tachycardia).